Champions Oncology (CSBR) Q1 2025 earnings summary

Executive summary

• Revenue grew 12% year-over-year to $14.1 million, marking a second consecutive quarter of growth and a return to profitability, with net income of $1.3 million reversing a $2.6 million loss in the prior year.

• Operational efficiencies, cost controls, and improved revenue conversion contributed to expanded profitability and positive adjusted EBITDA of $2.0 million.

• Management remains cautiously optimistic about sustaining the turnaround, though anticipates volatility in upcoming quarters.

• Cost reductions led to a 15.8% decrease in total costs and operating expenses, with notable declines in R&D and G&A expenses.

• Cash provided by operations was $311,000, with $2.9 million in cash and no debt at quarter-end.

Financial highlights

• Q1 revenue was $14.1 million, up 12% from the prior year.

• Net income reached $1.3 million, compared to a $2.6 million loss last year.

• Adjusted EBITDA was $2.0 million, versus a $1.7 million loss a year ago.

• Gross margin improved to 49.7%–50%, up from 38.8%–40% in the prior year.

• Cash generated from operations was $311,000, with $2.9 million in cash and no debt at quarter-end.

Outlook and guidance

• Management expects some volatility in revenue and EBITDA over the coming quarters but anticipates continued adjusted EBITDA profitability and long-term margins above 50% as revenue grows.

• No formal guidance provided for future quarters; uncertainty remains regarding the ability to raise additional capital if needed.

• The company is confident in its ability to deliver stronger financial results and create shareholder value.